Search by PDG name  
   

 

HRAS  
    


    
      Official symbol:  HRAS
      Full name:  HRas proto-oncogene, GTPase
      Location:  11p15.5
      Also known as:  HRAS1
      Entrez ID:  3265
      Ensembl ID:  ENSG00000174775
      Summary:  This gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, cognitive disability, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in this gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma. Multiple transcript variants, which encode different isoforms, have been identified for this gene. [provided by RefSeq, Jul 2008]

    

    
  Overall distribution
    
  Tissue specific distribution
    
 
  
 
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Gscore (Amp):  0.00  
Gscore (Del):  1.37  (Driver)
 
Recurrently deleted in 7 cancer type(s)
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Mscore:  1.61  (Driver)
 
Recurrently mutated in 8 cancer type(s)
   

    
  Overall
    
  Tissue specific
    
 
Total fusion occurrence:  1  
 
Fusions detected in 1 cancer type(s)
 
 

    
  Overall
    
  Tissue specific
    
   CRISPR: STRONGLY SELECTIVE 
 RNAi: STRONGLY SELECTIVE 
   
   

    
      Functional class:  Enzyme
      JensenLab PubMed score:  9975.82  (Percentile rank: 99.72%)
      PubTator score:  1733.76  (Percentile rank: 97.99%)
      Target development/druggability level:  TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below.
      Tractability (small molecule):  Discovery PrecedenceTargets with ligands; Targets with crystal structures with ligands
      Tractability (antibody):  Predicted Tractable - High confidenceTargets located in the plasma membrane; Targets with GO cell component terms plasma membrane or secreted

    







Contact us | | Terms & Conditions.
Copyright © 2020 University of Pennsylvania. All Rights Reserved.